https://drugnews.com.tw/articles/2026-07-10-fda-nasp-en.html Drugnews｜藥時事 en 2026-07-10T01:49:00.000Z Sobi's NASP Received an FDA CRL: The Problem Was Manufacturing Credibility, Not Efficacy https://drugnews.com.tw/articles/2026-07-10-fda-nasp.html Drugnews｜藥時事 zh-tw 2026-07-10T01:49:00.000Z 痛風新藥被 FDA 打回票：NASP 沒輸在療效，而是卡在製造可信度 https://drugnews.com.tw/articles/2026-07-09-japan-biotech-ecosystem-global-gap-en.html Drugnews｜藥時事 en 2026-07-09T01:30:00.000Z Why Has Japan Struggled to Build Global-Scale Biotech Companies? https://drugnews.com.tw/articles/2026-07-09-japan-biotech-ecosystem-global-gap.html Drugnews｜藥時事 zh-tw 2026-07-09T01:30:00.000Z 日本為什麼長不出全球級 Biotech？問題不在科學，而在產業生態